Key result
The endogenous antiinflammatory agent DEL-1 decreased blood pressure and cardiac and aortic hypertrophy in mouse models of hypertension by reducing immune cell recruitment.
Why the study?
Does developmental endothelial locus-1 (DEL-1) reduce blood pressure and cardiovascular damage in mouse models of hypertension?
Does developmental endothelial locus-1 (DEL-1) reduce blood pressure and cardiovascular damage in mouse models of hypertension?
Answers are grounded in this paper and cite their sources.
The endogenous antiinflammatory agent DEL-1 may offer a novel immunomodulatory approach to reducing hypertension-associated cardiovascular damage.
Cardiovascular diseases are a leading cause of mortality and disability worldwide. Hypertension, a major risk factor for these diseases, remains difficult to treat despite numerous drugs being available. In this issue of the JCI, Failer et al. show that the endogenous antiinflammatory agent developmental endothelial locus-1 (DEL-1) decreased blood pressure and cardiac and aortic hypertrophy in mouse models of hypertension through reduction in αvβ3 integrin-dependent metalloproteinase activity and immune cell recruitment, leading to reduced production of proinflammatory cytokines in cardiovascular tissues. This study offers an alternative in the treatment of hypertension-mediated organ damage through the immunomodulatory effect of DEL-1.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an editorial in Hypertension-associated cardiovascular damage. Developmental endothelial locus-1 (DEL-1) was evaluated. The endogenous antiinflammatory agent DEL-1 decreased blood pressure and cardiac and aortic hypertrophy in mouse models of hypertension by reducing immune cell recruitment.
Synapse has enriched 10 related papers. Consider them for comparative context: